email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2637-6628

Online Journal of Neurology and Brain Disorders

Mini Review(ISSN: 2637-6628)

Brivaracetam in epilepsy: A mini-review of the literature Volume 5 - Issue 3

Maria Stefanatou*

  • 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece

Received: March 8, 2021   Published:March 17, 2021

Corresponding author: Maria Stefanatou, 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece

DOI: 10.32474/OJNBD.2021.05.000214

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a high-affinity Synaptic Vesicle protein2A (SV2A) ligand that exceeds the binding potential of Levetiracetam (LEV). In the European Union, BRV is only approved as an adjunctive therapy for the treatment of Partial-Onset Seizures (POS) with or without secondary generalization, in patients 4 years of age and older with epilepsy, while F.D.A. has recently approved its use as monotherapy in partial-onset seizures in adults. In Phase III clinical trials, BRV has shown efficacy and an adequate safety profile in patients suffering from POS. In additional open-label studies, BRV has demonstrated satisfying results and high retention rates in patients with both focal – onset and genetic generalized epilepsies. The main Treatment-Emergent Adverse Events (TEAEs) observed during the regulatory and open label trials were somnolence, dizziness and headache following by fatigue and nausea. Brivaracetam seems to be an effective, easy to use and safe antiepileptic drug in clinical setting.

Abstract| Introduction| Brivaracetam| Conclusion| References|

https://www.high-endrolex.com/21